PanTera

Overview

Founded in Mol in 2022 as a joint venture between SCK CEN (Belgian Nuclear Research Centre) and IBA (Ion Beam Applications), PanTera is developing large-scale production capacity for actinium-225, a radioactive isotope used in targeted alpha therapy for cancer treatment.

Actinium-225 is in extremely short global supply relative to demand from pharmaceutical companies developing next-generation radiopharmaceutical drugs. PanTera's facility in Mol, which already hosts one of Europe's major nuclear research sites, is positioned to become a key supplier to this growing therapeutic category.

The company raised EUR 93M led by EQT Life Sciences as part of a EUR 134M total raise, the largest single life sciences funding round in Belgian history. The capital supports production scale-up and regulatory validation of supply chains for pharmaceutical-grade actinium-225.